Belatacept-Based Immunosuppression With Simultaneous Calcineurin Inhibitor Avoidance and Early Corticosteroid Withdrawal: A Prospective, Randomized Multicenter Trial.
Simultaneous calcineurin inhibitor avoidance (CNIA) and early corticosteroid withdrawal (ESW) has not been achieved primarily due to excessive acute rejection. This trial compared two belatacept-based CNIA/ESW regimens with a tacrolimus-based ESW regimen. Kidney transplant recipients were randomized to receive alemtuzumab/belatacept, or rabbit antithymocyte globulin (rATG)/belatacept, or rATG/ tacrolimus. The combinatorial primary endpoint consisted of patient death, renal allograft loss, or an MDRD calculated eGFR of <45 ml/min/1.73m2 at 12 months. Results are reported by treatment group: (alemtuzumab/belatacept, rATG/belatacept, rATG/tacrolimus). Superiority was not observed at one year for the primary endpoint (9/107 (8.4%), 15/104 (14.4%), 14/105 (13.3%), p=NS) for either belatacept-based regimen. Differences were not observed for secondary endpoints (death, death censored graft loss, or eGFR <45ml/min/1.73m2 ). Differences were observed in biopsy proven acute cellular rejection (BPACR) (10.3%/18.3%/1.9%) (p < 0.001), but not in antibody mediated rejection (BPAMR), mixed acute rejection (BPMAR), or de novo DSA. Neurologic and electrolyte abnormality adverse events were less frequent under belatacept. Belatacept-based CNIA/ESW regimens did not prove superior for the primary or secondary endpoints. Belatacept-treated patients demonstrated an increase in BPACR and reduced neurologic and metabolic adverse events. These results demonstrate that that simultaneous CNIA/ESW is feasible without excessive acute rejection.